Lobbying on 340B issues in 2023 remains on track for a record-breaking year, according to recently released congressional lobbying reports. [...] …
Year: 2023
The New York State Department of Health recently told a state trial court in Manhattan that two community health centers [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Enrollment in the 340B program was linked to diminished spending on charity care, according to preliminary findings from an ongoing [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
TIP: Ensure your 340B program has established ordering procedures and practices to optimize replenishment for maximum cost savings.
Generic and biosimilar drugmaker Sandoz today became the 28th pharmaceutical company to place conditions on 340B pricing involving drug shipments [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
GlaxoSmithKline (GSK) today became the fifth drug manufacturer to loosen or end its 340B contract pharmacy restrictions in Arkansas and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The recent end of a 340B program waiver for hospitals is wrong, hurts hospitals and their patients, and is bound [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal courts should allow enforcement of Arkansas’ 340B contract pharmacy law to continue unimpeded, an attorney representing Arkansas told a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The 340B program, enacted in 1992, enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
In 2010, the 340B program was expanded under the Affordable Care Act, allowing covered entities to contract with an unlimited number of contract pharmacies such as Walgreens to provide 340B discount drugs.
Since July 2020, over 25 unique drug manufactures have imposed restrictions impacting and limiting access to contract pharmacy arrangements. A deeper dive of these 340B restrictions are shared below.
- Claims Data Upload – Most manufacturers have partnered with 340B ESP to require covered entities to upload 340B claims data to access to their contract pharmacy network. Claims upload must follow a standardized format as required by 340B ESP or the manufacturer and uploaded at a recurring cadence to avoid disruption to 340B pricing access. Covered entities who are considering this option should seek counsel from within their organization
The community benefits provided by 340B hospitals surged by $16.5 billion, or 24%, in the latest year analyzed by a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
×
*Sign up for news summaries and alerts from 340B Report